A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata
In the register
The register attaches this trial to Amlitelimab (Sanofi), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Terminated early
- Declared phase
- Phase 2
- Sponsor
- Sanofi
- Participants (registry)
- 166
- Start
- June 2024
- Primary completion
- September 2025
- Study completion
- May 2026
- Last registry update
- August 2026
- Countries
- United States, Argentina, Australia, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Italy, Japan, Netherlands, Romania, Spain, United Kingdom
Conditions studied: Alopecia Areata
Interventions: Amlitelimab, SAR445229, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.